tetano
Editor, Senior Moderator
Vaccine
. 2022 Jan 28;S0264-410X(22)00057-3.
doi: 10.1016/j.vaccine.2022.01.033. Online ahead of print.
The cost-effectiveness of starting 23-valent pneumococcal polysaccharide vaccine and influenza vaccination at 50 vs. 65 years: A comparative modelling study
Hanyue Ding[SUP] 1 [/SUP], Junjie Huang[SUP] 1 [/SUP], Chun Ho Ngai[SUP] 1 [/SUP], Qingjie Sun[SUP] 1 [/SUP], Kin-On Kwok[SUP] 1 [/SUP], Harry Hx Wang[SUP] 2 [/SUP], Marc Chong[SUP] 1 [/SUP], Martin Cs Wong[SUP] 3 [/SUP]
Affiliations
Abstract
Objectives: Pneumococcal infection is a leading cause of morbidity and mortality. We aimed to evaluate the cost-effectiveness of 23-valent polysaccharide vaccine (PPV23) together with influenza vaccination or pneumococcal vaccination alone in adults starting from 50 years vs. 65 years in Hong Kong.
Methods: A hypothetical population of 100,000 older adults was included in a Markov model with age ranging from 50 to 85 years to calculate the cost and quality-adjusted life-years (QALYs) gained for vaccination strategies, including: (1) annual influenza vaccine and PPV23 at 50 and 65 years; (2) annual influenza vaccine and PPV23 at 65 years (similar with the current vaccination programme); (3) PPV23 at 50 and 65 years; (4) PPV23 at 65 years; and (5) no vaccination. We evaluated the incremental cost-effectiveness ratio (ICER) and used Monte Carlo simulation for probabilistic sensitivity analysis. The cost-effectiveness threshold was extracted from previous literature.
Results: In comparison with no vaccination, all strategies were cost-effective with ICERs less than the threshold (US$24,302 per QALY gained). When compared with no vaccination, strategies 1-4 saved US$ 49.5, US$ 94.9, US$ 584.3, and US$ 1114.2 to gain one QALY respectively. In comparison with strategy 2, strategy 1 spent US$ 195.3 to gain one QALY, whilst strategies 3 and 4 showed less effectiveness with increased costs.
Conclusions: All vaccination strategies were cost-effective, among which the strategy of PPV23 at 50/65 years with annual influenza vaccine was cost-effective even in comparison with current vaccination programme. These findings could help inform the design and implementation of vaccination strategies.
Keywords: Cost-effective analysis; Pneumococcal infection; Quality-adjusted life-years; Vaccine.
. 2022 Jan 28;S0264-410X(22)00057-3.
doi: 10.1016/j.vaccine.2022.01.033. Online ahead of print.
The cost-effectiveness of starting 23-valent pneumococcal polysaccharide vaccine and influenza vaccination at 50 vs. 65 years: A comparative modelling study
Hanyue Ding[SUP] 1 [/SUP], Junjie Huang[SUP] 1 [/SUP], Chun Ho Ngai[SUP] 1 [/SUP], Qingjie Sun[SUP] 1 [/SUP], Kin-On Kwok[SUP] 1 [/SUP], Harry Hx Wang[SUP] 2 [/SUP], Marc Chong[SUP] 1 [/SUP], Martin Cs Wong[SUP] 3 [/SUP]
Affiliations
- PMID: 35094867
- DOI: 10.1016/j.vaccine.2022.01.033
Abstract
Objectives: Pneumococcal infection is a leading cause of morbidity and mortality. We aimed to evaluate the cost-effectiveness of 23-valent polysaccharide vaccine (PPV23) together with influenza vaccination or pneumococcal vaccination alone in adults starting from 50 years vs. 65 years in Hong Kong.
Methods: A hypothetical population of 100,000 older adults was included in a Markov model with age ranging from 50 to 85 years to calculate the cost and quality-adjusted life-years (QALYs) gained for vaccination strategies, including: (1) annual influenza vaccine and PPV23 at 50 and 65 years; (2) annual influenza vaccine and PPV23 at 65 years (similar with the current vaccination programme); (3) PPV23 at 50 and 65 years; (4) PPV23 at 65 years; and (5) no vaccination. We evaluated the incremental cost-effectiveness ratio (ICER) and used Monte Carlo simulation for probabilistic sensitivity analysis. The cost-effectiveness threshold was extracted from previous literature.
Results: In comparison with no vaccination, all strategies were cost-effective with ICERs less than the threshold (US$24,302 per QALY gained). When compared with no vaccination, strategies 1-4 saved US$ 49.5, US$ 94.9, US$ 584.3, and US$ 1114.2 to gain one QALY respectively. In comparison with strategy 2, strategy 1 spent US$ 195.3 to gain one QALY, whilst strategies 3 and 4 showed less effectiveness with increased costs.
Conclusions: All vaccination strategies were cost-effective, among which the strategy of PPV23 at 50/65 years with annual influenza vaccine was cost-effective even in comparison with current vaccination programme. These findings could help inform the design and implementation of vaccination strategies.
Keywords: Cost-effective analysis; Pneumococcal infection; Quality-adjusted life-years; Vaccine.